Richard F. Pops
Known title: Director and CEO, Alkermes plcCIK: 0001126490
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Transaction History
| NBIX | ▲ Buy | Option Exercise | 3,318 | $0 | 5/21/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $718K | 5/15/2026 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $2.4M | 5/15/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 62,230 | $2.1M | 2/5/2026 | View on chart |
| ALKS | ▲ Buy | Grant | 149,580 | — | 2/5/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,869 | $0 | 5/22/2025 | View on chart |
| ALKS | ▲ Buy | Grant | 190,640 | — | 2/6/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 79,925 | $2.5M | 2/6/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 4,199 | $0 | 5/17/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,100 | $298K | 5/17/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 23,200 | $992K | 3/13/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 23,200 | $3.3M | 3/13/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 100 | $4K | 3/11/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 100 | $14K | 3/11/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,700 | $73K | 3/8/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 1,700 | $238K | 3/8/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $195K | 2/20/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $2.0M | 2/20/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 91,757 | $2.5M | 2/8/2024 | View on chart |
| ALKS | ▲ Buy | Grant | 218,551 | — | 2/8/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 32,400 | — | 2/21/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 14,386 | $399K | 2/21/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 53,145 | $1.5M | 2/20/2023 | View on chart |
| ALKS | ▲ Buy | Grant | 119,713 | — | 2/20/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $191K | 1/3/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $1.8M | 1/3/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 7,500 | $50K | 5/9/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 7,500 | $572K | 5/9/2022 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 7,500 | $50K | 5/9/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 7,500 | $572K | 5/9/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 120,847 | $2.0M | 5/6/2022 | View on chart |
| ALKS | ▼ Sell | Open Market | 93,747 | $2.6M | 5/6/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 329,153 | $5.4M | 5/5/2022 | View on chart |
| ALKS | ▼ Sell | Open Market | 221,222 | $6.2M | 5/5/2022 | View on chart |
| ALKS | ▼ Sell | Open Market | 32,288 | $923K | 5/5/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 32,400 | — | 2/21/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 14,386 | $361K | 2/21/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 18,125 | — | 2/16/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 8,038 | $215K | 2/16/2022 | View on chart |
| ALKS | ▲ Buy | Grant | 81,682 | $0 | 9/14/2021 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 36,267 | $1.1M | 9/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation
Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.